5 Key Takeaways
-
1
The video interview features John Tomtishen, Catalent’s Global Head of Cell Therapy Field Application Scientists and Strategic Alliances.
-
2
Tomtishen discusses his career and changes he has witnessed across the cell therapy field.
-
3
He explains why developers should prioritize product characterization early in development.
-
4
Tomtishen also emphasizes the importance of addressing chemistry, manufacturing, and controls early in development.
-
5
He discusses technologies and manufacturing strategies that could improve scalability and the industry’s efforts to bring future cell therapies to more patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
